Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jazz Pharma Plc (NQ: JAZZ )

110.41 +2.98 (+2.77%)
Streaming Delayed Price Updated: 3:29 PM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 324,453
Open 107.00
Bid (Size) 110.40 (2)
Ask (Size) 110.49 (1)
Prev. Close 107.43
Today's Range 106.73 - 110.82
52wk Range 106.61 - 146.70
Shares Outstanding 62,311,104
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 No-Brainer Stocks to Buy With $300 Right Now
A modest amount of money can go a long way on Wall Street when it's put to work in time-tested businesses with well-defined catalysts. 
Via The Motley Fool
Breaking Down Jazz Pharmaceuticals: 15 Analysts Share Their Views
Via Benzinga

Performance

YTD
-13.02%
-13.02%
1 Month
-6.38%
-6.38%
3 Month
-10.10%
-10.10%
6 Month
-14.33%
-14.33%
1 Year
-19.95%
-19.95%

More News

Read More
How To Make Your Cannabis Business More Attractive For Investors In 2024: Advice On Financial Health & Innovation
Via Benzinga
Topics Cannabis
Exposures Cannabis
The Analyst Landscape: 12 Takes On Jazz Pharmaceuticals
Via Benzinga
HC Wainwright & Co. Maintains Buy Rating for Jazz Pharmaceuticals: Here's What You Need To Know
Via Benzinga
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
Via InvestorPlace
Demystifying Jazz Pharmaceuticals: Insights From 4 Analyst Reviews
Via Benzinga
Evaluating Jazz Pharmaceuticals: Insights From 7 Financial Analysts
Via Benzinga
Decoding 6 Analyst Evaluations For Jazz Pharmaceuticals
Via Benzinga
Time Is Still The Enemy, Says Mom Who Moved Mountains For Her Epileptic Daughter & Still Advocates For Millions Of CBD Users
Via Benzinga
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
Via InvestorPlace
4 Exhilarating Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
Via The Motley Fool
Topics Stocks
Exposures US Equities
3 Cannabis Stocks That Could Be Multibaggers in the Making: February Edition
Via InvestorPlace
Topics Cannabis
Exposures Cannabis
The Queen Of Marijuana Investing Used Psychology To Launch Her Successful Cannabis Investment Fund
Via Benzinga
Topics Cannabis
Exposures Cannabis
3 Biotech Stocks to Buy on the Dip: February 2024
Via InvestorPlace
3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List
Via InvestorPlace
4 Eye-Catching Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
Via The Motley Fool
Topics Stocks
Exposures US Equities
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for January 2024
Via InvestorPlace
Topics Economy
Exposures Economy
Japanese University Will Research Marijuana's Medical Uses In First-Of-Its-Kind Collaboration With Australian Company
Via Benzinga
Topics Cannabis
Exposures Cannabis
2 Incredible Growth Stocks That Are Screaming Buys for 2024
Via The Motley Fool
4 Remarkable Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
Via The Motley Fool
Topics Stocks
Exposures US Equities
US Stocks Set To Open Weaker As Traders Eye Key Main Street Events: Analyst Sees Buying Opportunity On 'Stunning' Earnings Expectations
Via Benzinga
Topics Economy
Exposures Interest Rates
7 Growth Stocks Poised to Thrive in a Post-Fed Pivot World
Via InvestorPlace
Topics Economy
Exposures Interest Rates
Jazz Pharmaceuticals' Post-Traumatic Stress Disorder Drug Disappoints In Mid-Stage Study
Via Benzinga
3 No-Brainer Stocks to Buy With $500 Right Now
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.